How much revenue did Progyny generate this year?
Progyny has achieved a revenue of 1.17 B USD this year.
Progyny Revenue 2024
Progyny Revenue
1.17 B USD
Ticker
PGNY
ISIN
US74340E1038
WKN
A2PT5Q
In 2024, Progyny's sales reached 1.17 B USD, a 7.2% difference from the 1.09 B USD sales recorded in the previous year.
The Progyny Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 1.86 | 12,82 |
| 2028e | 1.68 | 14,19 |
| 2027e | 1.48 | 16,14 |
| 2026e | 1.31 | 18,22 |
| 2025e | 1.18 | 20,22 |
| 2024e | 1.17 | 20,46 |
| 2023 | 1.09 | 21,94 |
| 2022 | 0.79 | 21,26 |
| 2021 | 0.5 | 22,39 |
| 2020 | 0.34 | 20,32 |
| 2019 | 0.23 | 19,81 |
| 2018 | 0.11 | 18,41 |
| 2017 | 0.05 | 15,23 |
Progyny Revenue, EBIT, Net Income US74340E1038 · A2PT5Q
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Progyny, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Progyny from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Progyny’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Progyny. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Progyny’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Progyny’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Progyny’s growth potential.
Progyny Revenue, EBIT and net profit per share
| Date | Progyny Revenue | Progyny EBIT | Progyny Net Income |
|---|---|---|---|
| 2029e | 1.86 B undefined | 328.24 M undefined | 238.85 M undefined |
| 2028e | 1.68 B undefined | 292.54 M undefined | 206.28 M undefined |
| 2027e | 1.48 B undefined | 256.43 M undefined | 186.15 M undefined |
| 2026e | 1.31 B undefined | 197.16 M undefined | 77.51 M undefined |
| 2025e | 1.18 B undefined | 168.66 M undefined | 54.02 M undefined |
| 2024e | 1.17 B undefined | 170.75 M undefined | 47.71 M undefined |
| 2023 | 1.09 B undefined | 62.18 M undefined | 62.04 M undefined |
| 2022 | 786.9 M undefined | 23.3 M undefined | 30.4 M undefined |
| 2021 | 500.6 M undefined | 32.3 M undefined | 65.8 M undefined |
| 2020 | 344.9 M undefined | 9.2 M undefined | 46.5 M undefined |
| 2019 | 229.7 M undefined | 12.1 M undefined | -8.6 M undefined |
| 2018 | 105.4 M undefined | -3.5 M undefined | -5.5 M undefined |
| 2017 | 48.6 M undefined | -11 M undefined | -13.5 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2017 | 48.6 M USD | -11 M USD | -13.5 M USD |
| 2018 | 105.4 M USD | -3.5 M USD | -5.5 M USD |
| 2019 | 229.7 M USD | 12.1 M USD | -8.6 M USD |
| 2020 | 344.9 M USD | 9.2 M USD | 46.5 M USD |
| 2021 | 500.6 M USD | 32.3 M USD | 65.8 M USD |
| 2022 | 786.9 M USD | 23.3 M USD | 30.4 M USD |
| 2023 | 1.09 B USD | 62.18 M USD | 62.04 M USD |
| 2024e | 1.17 B USD | 170.75 M USD | 47.71 M USD |
| 2025e | 1.18 B USD | 168.66 M USD | 54.02 M USD |
| 2026e | 1.31 B USD | 197.16 M USD | 77.51 M USD |
| 2027e | 1.48 B USD | 256.43 M USD | 186.15 M USD |
| 2028e | 1.68 B USD | 292.54 M USD | 206.28 M USD |
| 2029e | 1.86 B USD | 328.24 M USD | 238.85 M USD |
Progyny stock margins US74340E1038 · A2PT5Q
The Progyny margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Progyny. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Progyny.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Progyny's sales revenue. A higher gross margin percentage indicates that the Progyny retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Progyny's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Progyny's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Progyny's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Progyny. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Progyny's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Progyny Margin History
| Progyny Gross margin | Progyny Profit margin | Progyny EBIT margin | Progyny Profit margin |
|---|---|---|---|
| 2029e | 21.94 % | 17.63 % | 12.83 % |
| 2028e | 21.94 % | 17.38 % | 12.26 % |
| 2027e | 21.94 % | 17.33 % | 12.58 % |
| 2026e | 21.94 % | 15.04 % | 5.91 % |
| 2025e | 21.94 % | 14.28 % | 4.57 % |
| 2024e | 21.94 % | 14.63 % | 4.09 % |
| 2023 | 21.94 % | 5.71 % | 5.7 % |
| 2022 | 21.26 % | 2.96 % | 3.86 % |
| 2021 | 22.39 % | 6.45 % | 13.14 % |
| 2020 | 20.32 % | 2.67 % | 13.48 % |
| 2019 | 19.81 % | 5.27 % | -3.74 % |
| 2018 | 18.41 % | -3.32 % | -5.22 % |
| 2017 | 15.23 % | -22.63 % | -27.78 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2017 | 15.23 % | -22.63 % | -27.78 % |
| 2018 | 18.41 % | -3.32 % | -5.22 % |
| 2019 | 19.81 % | 5.27 % | -3.74 % |
| 2020 | 20.32 % | 2.67 % | 13.48 % |
| 2021 | 22.39 % | 6.45 % | 13.14 % |
| 2022 | 21.26 % | 2.96 % | 3.86 % |
| 2023 | 21.94 % | 5.71 % | 5.7 % |
| 2024e | 21.94 % | 14.63 % | 4.09 % |
| 2025e | 21.94 % | 14.28 % | 4.57 % |
| 2026e | 21.94 % | 15.04 % | 5.91 % |
| 2027e | 21.94 % | 17.33 % | 12.58 % |
| 2028e | 21.94 % | 17.38 % | 12.26 % |
| 2029e | 21.94 % | 17.63 % | 12.83 % |
Progyny Aktienanalyse
What does Progyny do?
Progyny Inc. is a company specializing in reproductive medicine and fertility treatments. It was founded in New York City in 2008 and has been listed on the NASDAQ stock exchange since 2019. The idea for Progyny arose when founder Gina Bartasi herself had difficulty getting pregnant and was searching for support and transparent information. She recognized the need to offer a better and more accessible service for people with fertility problems, thus founding Progyny. Progyny's business model is to offer employers a fertility benefit to help their employees, especially women, with family planning. It provides customized fertility treatments and financial assistance through its innovative programs. This allows employers to position themselves as progressive and inclusive while also increasing the bond and well-being of their employees. The different divisions of Progyny include fertility management, fertility measurement and monitoring, and fertility benefits. The fertility management solutions provide companies with comprehensive care for their employees, including counseling and support on fertility and family planning. They also provide access to an exclusive network practice specializing in reproductive medicine, including in vitro fertilization (IVF) and egg donation. The fertility measurement and monitoring program offers a personalized fertility profile that allows employees to track their fertility status to maximize their chances of a successful pregnancy. Progyny utilizes advanced methods of artificial intelligence and machine learning for this purpose. Progyny's fertility benefits include financial support for fertility treatments and medications that are not normally covered by health insurance. Additionally, the company offers a unique membership option that provides unlimited access to master fertility practices for one year. Progyny also offers a comprehensive patient experience through world-leading doctors and a patented technology platform. The platform provides support in navigating the fertility process and ensures that patients receive the best possible medical and financial care. Overall, Progyny has a significant impact on the field of reproductive medicine. With an innovative solution tailored to the needs of employers and strong support for aspiring parents, the company achieves a higher success rate in pregnancy compared to traditional fertility treatments. Progyny's technology platform improves workflow efficiency and communication in the practice, leading to a better patient experience and greater engagement. Overall, Progyny offers a holistic solution for employers and employees tailored to the unique challenges of family planning and fertility. With innovative approaches and a focus on the well-being of female employees, the company has taken a unique position in the market and is expected to continue to play a strong role in the industry. Progyny ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Progyny's Sales Figures
The sales figures of Progyny originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Progyny’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Progyny's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Progyny’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Progyny stock
How much was the turnover of the company Progyny compared to the previous year?
The revenue of Progyny has increased by 7.2% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Progyny?
The revenue of Progyny is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Progyny measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Progyny so important for investors?
The revenue of Progyny is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Progyny pay?
Over the past 12 months, Progyny paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Progyny is expected to pay a dividend of 0 USD.
What is the dividend yield of Progyny?
The current dividend yield of Progyny is .
When does Progyny pay dividends?
Progyny pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Progyny?
Progyny paid dividends every year for the past 0 years.
What is the dividend of Progyny?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Progyny located?
Progyny is assigned to the 'Health' sector.
Wann musste ich die Aktien von Progyny kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Progyny from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Progyny pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Progyny in the year 2023?
In the year 2023, Progyny distributed 0 USD as dividends.
In which currency does Progyny pay out the dividend?
The dividends of Progyny are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Progyny
Our stock analysis for Progyny Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Progyny Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
